A Pilot Phase II Trial of Hypofractionated Intensity-Modulated Radiation Therapy (Hypo-IMRT) Combining With Temozolomide (TMZ) and Bevacizumab for Patients With Newly Diagnosed Glioblastoma Multiforme (GBM).
Phase of Trial: Phase II
Latest Information Update: 14 Jun 2017
At a glance
- Drugs Bevacizumab (Primary) ; Temozolomide
- Indications Glioblastoma
- Focus Therapeutic Use
- 08 Jun 2017 Status changed from active, no longer recruiting to completed.
- 14 Sep 2015 Planned End Date changed from 1 Dec 2015 to 1 Aug 2017 as reported byClinicalTrials.gov record.
- 06 May 2014 According to the ClinicalTrials.gov record, planned end date changed from 1 Dec 2014 to 1 Dec 2015.